Diagnostic Accuracy of 131I Scanning with Recombinant Human Thyrotropin versus Thyroid Hormone Withdrawal in a Patient with Metastatic Thyroid Carcinoma and Hypopituitarism

Matthew D. Ringel, Paul W. Ladenson

Research output: Contribution to journalArticlepeer-review

Abstract

The diagnostic and therapeutic use of radioactive iodine in patients with thyroid cancer requires a sufficient serum concentration of thyrotropin (TSH) for efficient thyroid tissue uptake of radioiodine. Recombinant human TSH (rhTSH) is a promising new agent, which appears to facilitate radioiodine scanning with similar efficacy to thyroid hormone withdrawal without the immunologie side-effects of bovine TSH (bTSH) administration. Patients with thyroid cancer and concomitant secondary hypothyroidism are particularly difficult to treat because of their inability to elevate endogenous TSH and the limitations of bTSH administration. We describe a patient with metastatic thyroid carcinoma and secondary hypothyroidism with metastases visible only after administration of rhTSH previously unappreciated on thyroid hormone withdrawal scans. This patient exemplifies the usefulness of rhTSH administration before radioactive iodine for this group of patients.

Original languageEnglish (US)
Pages (from-to)1724-1725
Number of pages2
JournalJournal of Clinical Endocrinology and Metabolism
Volume81
Issue number5
DOIs
StatePublished - 1996

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Diagnostic Accuracy of <sup>131</sup>I Scanning with Recombinant Human Thyrotropin versus Thyroid Hormone Withdrawal in a Patient with Metastatic Thyroid Carcinoma and Hypopituitarism'. Together they form a unique fingerprint.

Cite this